title: Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
abstract: To evaluate the effects of 1-year treatment with orlistat plus L-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and inflammatory parameters in obese type 2 diabetic patients. Two hundred and fifty-eight patients with uncontrolled type 2 diabetes mellitus (T2DM) [glycated hemoglobin (HbA(1c)) > 8.0%] in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomized to take orlistat 120 mg three times a day plus L-carnitine 2 g one time a day or orlistat 120 mg three times a day. We evaluated the following parameters at baseline and after 3, 6, 9, and 12 months: body weight, body mass index (BMI), glycated hemoglobin (HbA(1c) ), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (Tg), adiponectin (ADN), leptin, tumor necrosis factor-α (TNF-α), vaspin, and high-sensitivity C-reactive protein (Hs-CRP). We observed a better decrease in body weight, glycemic profile, HOMA-IR, LDL-C, and ADN and a faster improvement in FPI, TC, Tg, leptin, TNF-α, Hs-CRP with orlistat plus L-carnitine compared to orlistat alone. We also recorded an improvement in vaspin with orlistat plus l-carnitine not reached with orlistat alone. Orlistat plus L-carnitine gave a better improvement in body weight, glycemic and lipid profile compared to orlistat alone; furthermore, a faster and better improvement in inflammatory parameters was observed with orlistat plus L-carnitine compared to orlistat alone.
authors.affiliation: Fondazione IRCCS Policlinico S. Matteo, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, P.le C. Golgi, 2-27100 Pavia, Italy. giuseppe.derosa@unipv.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Derosa
authors.forename: Pamela
authors.initials: P
authors.lastname: Maffioli
authors.forename: Ilaria
authors.initials: I
authors.lastname: Ferrari
authors.forename: Angela
authors.initials: A
authors.lastname: D'Angelo
authors.forename: Elena
authors.initials: E
authors.lastname: Fogari
authors.forename: Ilaria
authors.initials: I
authors.lastname: Palumbo
authors.forename: Sabrina
authors.initials: S
authors.lastname: Randazzo
authors.forename: Arrigo F G
authors.initials: AF
authors.lastname: Cicero
mesh_terms: D052242:Adiponectin / Q000097:blood; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D001835:Body Weight; D002097:C-Reactive Protein / Q000378:metabolism; D002331:Carnitine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D020738:Leptin / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000178:diet therapy / Q000188:drug therapy* / Q000378:metabolism; D000077403:Orlistat; D045162:Thiazolidinediones / Q000009:adverse effects / Q000494:pharmacology; D013997:Time Factors
chemical_list: D052242:Adiponectin; D000893:Anti-Inflammatory Agents; D019440:Anti-Obesity Agents; D001786:Blood Glucose; D002097:C-Reactive Protein; D002331:Carnitine; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D007783:Lactones; D020738:Leptin; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D000077403:Orlistat; D045162:Thiazolidinediones